E. Willard

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy

S. Watson, S. Charlton, D. Sykes, 2016, Molecular Pharmacology.

Fevipiprant ( QAW 039 ) , a Slowly Dissociating CRTh 2 Antagonist with the Potential for Improved Clinical Efficacy s

S. Watson, S. Charlton, D. Sykes, 2016 .

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

D. Budd, S. Watson, S. Charlton, 2017, ACS medicinal chemistry letters.

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

H. Heidbuchel, D. Atar, J. Le Heuzey, 2021, BMC Medicine.

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy

S. Watson, S. Charlton, D. Sykes, 2016, Molecular Pharmacology.